OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
18
Results
Show all
Save search
Copy query
Show results for
Unknown
(18)
Publication Date
Release Date
2021
(7)
2024
(4)
2025
(2)
2023
(2)
2022
(1)
2020
(1)
2016
(1)
Previous
page
1 / 2
You're on page
1
page
2
Next
page
Sort
by:
Relevance
Page size
10
Effects of empagliflozin on quality of life and healthcare use and costs in chronic kidney disease: a health economic analysis of the EMPA-KIDNEY trial.
Not available
S-EPMC12274867
|
biostudies-literature
Cite
A second update on mapping the human genetic architecture of COVID-19.
Not available
S-EPMC10482689
|
biostudies-literature
Cite
Mapping the human genetic architecture of COVID-19.
Not available
S-EPMC8674144
|
biostudies-literature
Cite
Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease.
Not available
S-EPMC7616743
|
biostudies-literature
Cite
Frailty, Multimorbidity, and Polypharmacy: Exploratory Analyses of the Effects of Empagliflozin from the EMPA-KIDNEY Trial.
Not available
S-EPMC11390031
|
biostudies-literature
Cite
Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial.
Not available
S-EPMC7615591
|
biostudies-literature
Cite
Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial.
Not available
S-EPMC7618536
|
biostudies-literature
Cite
Empagliflozin in Patients with Chronic Kidney Disease.
Not available
S-EPMC7614055
|
biostudies-literature
Cite
Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition).
Not available
S-EPMC4835977
|
biostudies-literature
Cite
Delaying surgery for patients with a previous SARS-CoV-2 infection.
Not available
S-EPMC7537063
|
biostudies-literature
Cite
Previous
page
1 / 2
You're on page
1
page
2
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets